Diabetes-Specific Oral Nutritional Supplement Improves Postprandial Glycemic Response in Prediabetes

Why this study matters

People with prediabetes need foods that keep post-meal glucose from spiking. That is the core challenge for any product aimed at glycemic control. A new paper in Nutrition Research and Practice (DOI: 10.4162/nrp.2025.19.6.904) tested a diabetes-specific oral nutritional supplement (DSNF) against a standard oral nutritional supplement (ONS). The results are hard to ignore.

The DSNF cut postprandial glucose incremental area under the curve by about 62%. That is a major difference for one 200 mL serving.

Background: ONS and prediabetes

Oral nutritional supplements deliver calories, protein, and micronutrients in a convenient drink. In this study, the standard ONS contained no allulose and had more available carbohydrate than the DSNF. That profile can be a problem for someone with prediabetes.

The diabetes-specific formula used two levers. It lowered available carbohydrate. It also added 3 g of allulose per 200 mL. Allulose did more than replace sweetness. According to the study's discussion, allulose inhibits glucose absorption, stimulates GLP-1 release, and promotes hepatic glycogen storage. Those actions work together to shape the post-meal glucose curve.

What the study did

Researchers compared postprandial glucose responses after a 200 mL serving of DSNF versus a standard ONS. The DSNF contained 3 g of allulose. The standard ONS contained 0 g. The DSNF also contained less available carbohydrate.

The measured outcome was postprandial glucose iAUC, or incremental area under the curve. This captures the full glucose response, not just a single reading.

Key findings

The difference was decisive. The DSNF produced an iAUC of 1,683.49. The standard ONS produced 4,455.92. The P value was less than 0.0001.

Parameter	DSNF (allulose formula)	Standard ONS
Allulose per 200 mL	3 g	0 g
Available carbohydrate	Lower	Standard
Postprandial glucose iAUC	1,683.49	4,455.92

The allulose-containing formula cut the glucose response by more than half.

What it means for manufacturers

This study gives formulators a clear direction. Allulose can function as an active ingredient in products for adults with prediabetes, not just as a sweetener.

The 3 g dose is practical for a ready-to-drink beverage. It is an amount that can be formulated into existing oral nutrition products. Combined with lower available carbohydrate, allulose appears to drive a meaningful improvement in glycemic response.

The mechanism matters too. If allulose works by inhibiting glucose absorption, stimulating GLP-1, and supporting hepatic glycogen storage, then product developers can position it beyond sugar replacement. This is evidence for the prediabetes space. For ingredient buyers, this supports allulose as a strategic purchase for clinical nutrition applications.

Questions formulators ask

How much allulose was used?

The active formula contained 3 g per 200 mL serving. That's a straightforward dose for a beverage.

Why did the DSNF perform so much better?

The DSNF combined 3 g of allulose with lower available carbohydrate. The study's authors attribute allulose's role to three mechanisms: inhibition of glucose absorption, stimulation of GLP-1 release, and promotion of hepatic glycogen storage.

Can standard sweeteners replace allulose here?

Standard sweeteners can reduce sugar content, but they do not have the same documented metabolic effects. This study specifically supports allulose as a functional contributor to glycemic control.

Final thoughts

No single study closes the book on product claims. But this one makes a strong case for allulose in diabetes-specific oral nutrition. The iAUC difference is large. The serving size is realistic. The mechanism is coherent. For formulators targeting prediabetes, that is a worthwhile direction to test.